TNFi Not Linked to Increased Cancer Recurrence in RA Patients

Share this content:
TNFi Not Linked to Increased Cancer Recurrence in RA Patients
TNFi Not Linked to Increased Cancer Recurrence in RA Patients

FRIDAY, Aug. 24, 2018 (HealthDay News) -- For patients with rheumatoid arthritis (RA), treatment with tumor necrosis factor inhibitors (TNFi) is not associated with increased risk for cancer recurrence, according to a study published online Aug. 14 in the Annals of Internal Medicine.

Pauline Raaschou, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues conducted a population-based cohort study based on linkage of nationwide registers to examine whether TNFi treatment in RA is associated with increased risk for cancer recurrence.

The researchers found that 42 of the 467 patients who started TNFi treatment at a mean of 7.9 years after cancer diagnosis had cancer recurrence (9.0 percent); 155 of 2,164 matched patients with the same cancer history had recurrences (7.2 percent) (hazard ratio, 1.06; 95 percent confidence interval, 0.73 to 1.54). In analyses of subsets of patients matched on cancer stage or with similar time from index cancer diagnosis to the start of TNFi treatment and in unmatched analyses, the hazard ratios were close to 1.

"The findings suggest that TNFi treatment is not associated with increased risk for cancer recurrence in patients with RA, although meaningful risk increases could not be ruled out completely," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

High Uptake, Acceptability of Rapid Fentanyl Test Strips

High Uptake, Acceptability of Rapid Fentanyl Test Strips

Significant link between receiving positive results, reporting positive change in overdose risk behavior

ACR: Walking Each Day May Cut Risk for TKA Over Five Years

ACR: Walking Each Day May Cut Risk for ...

Replacing 5 minutes of non-walking time with 5 minutes of moderate-to-vigorous walking beneficial

Short Respiratory Event Duration Ups Mortality Risk in OSA

Short Respiratory Event Duration Ups Mortality Risk in ...

Individuals with shortest-duration events had adjusted hazard ratio of 1.31 for all-cause mortality

is free, fast, and customized just for you!




Already a member?

Sign In Now »